534 related articles for article (PubMed ID: 12637112)
21. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L
Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659
[TBL] [Abstract][Full Text] [Related]
22. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
Coutinho W
Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):262-70. PubMed ID: 19466219
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Viner RM; Hsia Y; Tomsic T; Wong IC
Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
[TBL] [Abstract][Full Text] [Related]
24. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Halford JC
Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
[TBL] [Abstract][Full Text] [Related]
26. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
[TBL] [Abstract][Full Text] [Related]
27. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Rubio MA; Gargallo M; Isabel Millán A; Moreno B
Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
[TBL] [Abstract][Full Text] [Related]
28. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio MJ; Wilton LV; Shakir SA
Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
[TBL] [Abstract][Full Text] [Related]
29. Orlistat--a novel weight loss therapy.
Lucas KH; Kaplan-Machlis B
Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530
[TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy for obesity.
Ioannides-Demos LL; Proietto J; McNeil JJ
Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
[TBL] [Abstract][Full Text] [Related]
31. Long-term pharmacotherapy for obesity.
Klein S
Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
[TBL] [Abstract][Full Text] [Related]
32. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
34. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chou KM; Huang BY; Fanchiang JK; Chen CH
Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Kim C; Lau J
Arch Intern Med; 2004 Jul; 164(13):1395-404. PubMed ID: 15249348
[TBL] [Abstract][Full Text] [Related]
37. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
[TBL] [Abstract][Full Text] [Related]
38. What are the risks and the benefits of current and emerging weight-loss medications?
Robinson JR; Niswender KD
Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
[TBL] [Abstract][Full Text] [Related]
39. A benefit-risk assessment of sibutramine in the management of obesity.
Nisoli E; Carruba MO
Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
[TBL] [Abstract][Full Text] [Related]
40. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]